BrightGene Bio Medical Technology C (688166) fair value: what the stock is really worth
We calculate from audited financials what BrightGene Bio Medical Technology C is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch BrightGene Bio Medical Technology C for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ¥17.39 – ¥116.49 · fair‑value band ¥13.35 – ¥22.20 · the ¥35.23 price screens above the ¥18.45 fair value. Dashed = 300-day average. As of Sep 13, 2026.
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally.
Show more
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, oncology, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, digestion, and others. In addition, the company is involved in technology research and development; transfer of biomedical products; import, export, wholesale, and retail of medicines; production and operation of medical devices; and technical services. BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.
Stock analysis
BrightGene Bio Medical Technology C (688166) currently trades at ¥35.23, while our model-based Fair Value estimate is ¥18.45, implying the stock looks roughly 90.9% overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of ¥4.34 per share, and 0 of the 16 models we run sit above the ¥35.23 price.
Bear case: the Multiples group reads lowest at ¥2.31, and 16 of the 16 models stay below the price. Evidence for this calculation is medium.
Scenario range: ¥13.35 (bear) to ¥22.20 (bull), the price of ¥35.23 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
BrightGene Bio Medical Technology C reported revenue of 1.2B CNY in FY2025 versus 1.1B CNY in FY2021, a compound +3.8%/yr. Reported net income was 54.5M CNY in FY2025, compounding −31.2%/yr from FY2021.
Key figures
Market cap 17.8B CNY (≈ $2.7B) · P/E ratio 293.6 · P/S ratio 13.1 · EPS (TTM) ¥0.1200 · Dividend yield 0.0% · Net margin 4.5% · Return on equity 1.9% · Return on assets (EBIT) 5.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 71% below its 52-week high, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −48%, 688166 screens richer than that median.
Fair Value models
Bear ¥13.35Fair Value ¥18.45Bull ¥22.20
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (¥0.0732 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−4.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.2%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−20.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−20.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 9%
⚠ Revenue per share shrinking 13.9%/yr over ~6Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare BrightGene Bio Medical Technology C with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 645 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Above median
Profitability
Return on equity (TTM)2% · Above median
Return on assets1% · Above median
Net margin (TTM)4% · Below median
Operating margin (TTM)4% · Above median
Growth and dividend
Revenue growth31% · Top 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.55× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)293.6× · Priciest 25%
P/B7.06× · Priciest 25%
P/S (TTM)13.70× · Priciest 25%
EV/EBITDA82.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)7· sector 0
HEALTH (low debt)72· sector 97
DIVIDEND (yield)1· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BrightGene Bio Medical Technology C Fair Value". https://www.fairvalue-calculator.com/stock/688166
Frequently asked questions
Is BrightGene Bio Medical Technology C (688166) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ¥18.45 versus a price of ¥35.23, about −48% upside (overvalued).
What is the fair value of 688166?
Our model-based fair value for BrightGene Bio Medical Technology C is ¥18.45 (as of Sep 13, 2026), built from audited fundamentals. The current price: ¥35.23.
What is the quality score of 688166?
BrightGene Bio Medical Technology C has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BrightGene Bio Medical Technology C (688166)?
Our model-based price target is the fair value of ¥18.45 (as of Sep 13, 2026) from 16 valuation models. Cautious scenario ¥13.35, optimistic scenario ¥22.20. It is a calculation from audited fundamentals, not an analyst target.
What is the BrightGene Bio Medical Technology C stock forecast for 2026?
Our models put fair value at ¥18.45, about −48% upside versus a price of ¥35.23 (overvalued). Cautious scenario ¥13.35, optimistic scenario ¥22.20. The calculation is refreshed regularly with new filings.
What is the revenue of BrightGene Bio Medical Technology C (688166)?
BrightGene Bio Medical Technology C reported trailing-twelve-month revenue of about 1.3B CNY (latest available figure, as of Sep 13, 2026).
Does BrightGene Bio Medical Technology C pay a dividend?
BrightGene Bio Medical Technology C currently shows a dividend yield of about 0.05% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of BrightGene Bio Medical Technology C (688166)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BrightGene Bio Medical Technology C it is ¥18.45 per share (as of Sep 13, 2026), against a price of ¥35.23. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is BrightGene Bio Medical Technology C stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 688166 trades above its calculated fair value: price ¥35.23, fair value ¥18.45, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688166?
No. The price is what the market pays today (¥35.23); the fair value is what the company's own numbers justify (¥18.45). For BrightGene Bio Medical Technology C the two are ¥16.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is BrightGene Bio Medical Technology C worth?
The market values BrightGene Bio Medical Technology C at about 17.8B CNY (market capitalisation, as of Sep 13, 2026). Per share that is ¥35.23; our models calculate a fair value of ¥18.45 per share.
What do the bullish and bearish scenarios say about 688166?
Our models span a range for BrightGene Bio Medical Technology C: cautious scenario ¥13.35, base ¥18.45, optimistic ¥22.20 per share (as of Sep 13, 2026, price ¥35.23). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688166?
BrightGene Bio Medical Technology C trades at a price-to-earnings ratio of 293.6 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥18.45 is built from several models across several years. Other multiples: P/B 7.1, P/S 13.7, EV/EBITDA 82.6.
How solid is the balance sheet of BrightGene Bio Medical Technology C (688166)?
Balance-sheet figures for BrightGene Bio Medical Technology C (as of Sep 13, 2026): return on equity 1.9%, debt of 0.55 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 688166 from its 52-week high?
BrightGene Bio Medical Technology C trades at ¥35.23, about 71% below its 52-week high of ¥122.59 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥18.45 is for.
Which stocks are comparable to BrightGene Bio Medical Technology C?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BrightGene Bio Medical Technology C stock attractive at the current price?
The data as of Sep 13, 2026: price ¥35.23, calculated fair value ¥18.45 (−48%), Quality Score 44/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688166 calculated?
We run BrightGene Bio Medical Technology C through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥18.45, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. BrightGene Bio Medical Technology C itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with BrightGene Bio Medical Technology C right now?
The price sits above even our optimistic bull case (¥22.20). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of BrightGene Bio Medical Technology C
How large is the market capitalisation of BrightGene Bio Medical Technology C (688166)?
The market capitalisation of BrightGene Bio Medical Technology C is 17.8B CNY (≈ $2.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BrightGene Bio Medical Technology C (688166)?
The price-to-sales ratio of BrightGene Bio Medical Technology C is 13.1 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BrightGene Bio Medical Technology C (688166)?
Earnings per share at BrightGene Bio Medical Technology C are ¥0.1200 (price ÷ EPS = P/E 293.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BrightGene Bio Medical Technology C (688166)?
The dividend yield of BrightGene Bio Medical Technology C is 0.0% (payout 13.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BrightGene Bio Medical Technology C (688166)?
The net margin of BrightGene Bio Medical Technology C is 4.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BrightGene Bio Medical Technology C (688166)?
The return on equity (ROE) of BrightGene Bio Medical Technology C is 1.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BrightGene Bio Medical Technology C (688166)?
On an EBIT basis the return on assets of BrightGene Bio Medical Technology C is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BrightGene Bio Medical Technology C (688166)?
The operating margin of BrightGene Bio Medical Technology C is 3.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BrightGene Bio Medical Technology C (688166)?
Revenue at BrightGene Bio Medical Technology C is growing +30.5% versus a year earlier (3y avg +6.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BrightGene Bio Medical Technology C (688166)?
Earnings per share at BrightGene Bio Medical Technology C are growing −33.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BrightGene Bio Medical Technology C (688166) generate?
The free cash flow of BrightGene Bio Medical Technology C is −128M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BrightGene Bio Medical Technology C (688166) carry?
The net debt of BrightGene Bio Medical Technology C is 538M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BrightGene Bio Medical Technology C in the live analysis
One click puts BrightGene Bio Medical Technology C on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
